Zahra Hajmohammadi1, Mojtaba Heydari1, Majid Nimrouzi2, Pouya Faridi3, Mohammad Javad Zibaeenezhad4, Gholamhossein Ranjbar Omrani5, Mesbah Shams6. 1. Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz 98713, Iran. 2. Department of Traditional Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz 98713, Iran. 3. Department of Phytopharmaceuticals, School of Pharmacy and Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran. 4. Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran. 5. Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran. 6. Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran. Electronic address: shams@sums.ac.ir.
Abstract
BACKGROUND: Lipid-lowering effect of Rhus coriaria L. (Rhus) has been investigated in multiple animal studies with promising results. Nonetheless, its clinical efficacy has not been adequately examined. OBJECTIVE: The aim of this study was to evaluate the lipid-lowering effects of Rhus among patients with hyperlipidemia. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: The study was designed as a two-arm, double-blind placebo-controlled randomized clinical trial, using a parallel design. Eighty patients with primary hyperlipidemia were randomly assigned to receive Rhus capsules or placebo for 6 weeks. MAIN OUTCOME MEASURES: The serum lipid levels, apolipoprotein-A1 (Apo-A1) and apolipoprotein-B (Apo-B) were measured. RESULTS:Mean serum high-density lipoprotein cholesterol (HDL-C) and Apo-A1 levels were significantly increased in the Rhus group, compared with the placebo group, after 6 weeks of intervention (P = 0.001). The analysis of covariance test including age, gender, body mass index (BMI), and smoking as co-variables revealed that the increase in HDL-C and Apo-A1 levels remained significant, and increases in HDL-C were dependent on the increase in Apo-A1 levels. No significant difference was observed between Rhus and placebo groups in terms of mean reductions in total cholesterol, low-density lipoprotein cholesterol and triglyceride levels; however, more significant improvement was observed among obese patients (BMI ≥ 30 kg/m2). CONCLUSION: The study showed significant increases in HDL-C and Apo-A1 levels in response to Rhus supplementation in patients with hyperlipidemia. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT02295293.
RCT Entities:
BACKGROUND:Lipid-lowering effect of Rhus coriaria L. (Rhus) has been investigated in multiple animal studies with promising results. Nonetheless, its clinical efficacy has not been adequately examined. OBJECTIVE: The aim of this study was to evaluate the lipid-lowering effects of Rhus among patients with hyperlipidemia. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: The study was designed as a two-arm, double-blind placebo-controlled randomized clinical trial, using a parallel design. Eighty patients with primary hyperlipidemia were randomly assigned to receive Rhus capsules or placebo for 6 weeks. MAIN OUTCOME MEASURES: The serum lipid levels, apolipoprotein-A1 (Apo-A1) and apolipoprotein-B (Apo-B) were measured. RESULTS: Mean serum high-density lipoprotein cholesterol (HDL-C) and Apo-A1 levels were significantly increased in the Rhus group, compared with the placebo group, after 6 weeks of intervention (P = 0.001). The analysis of covariance test including age, gender, body mass index (BMI), and smoking as co-variables revealed that the increase in HDL-C and Apo-A1 levels remained significant, and increases in HDL-C were dependent on the increase in Apo-A1 levels. No significant difference was observed between Rhus and placebo groups in terms of mean reductions in total cholesterol, low-density lipoprotein cholesterol and triglyceride levels; however, more significant improvement was observed among obesepatients (BMI ≥ 30 kg/m2). CONCLUSION: The study showed significant increases in HDL-C and Apo-A1 levels in response to Rhus supplementation in patients with hyperlipidemia. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT02295293.
Authors: Rabia Shabir Ahmad; Muhammad Bilal Hussain; Muhammad Tauseef Sultan; Muhammad Sajid Arshad; Marwa Waheed; Mohammad Ali Shariati; Sergey Plygun; Mohammad Hashem Hashempur Journal: Evid Based Complement Alternat Med Date: 2020-05-10 Impact factor: 2.629